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Background: Perihilar cholangiocarcinoma (PHCCA) remains a surgical challenge for which few large
Western series have been reported. The aims of this study were to investigate the results of surgical
resection for PHCCA and assess how practice has evolved over the past 15 years.
Methods: A prospectively maintained database was interrogated to identify all resections. Clinicopatho-
logical data were analysed for impact on survival. Subsequently, data for resections carried out during the
periods 1994–1998, 1999–2003 and 2004–2008 were compared.
Results: Eighty-three patients underwent resection. Trisectionectomy was required in 67% of resec-
tions. Overall survival was 70%, 36% and 20% at 1, 3 and 5 years, respectively. Size of tumour, margin
(R0) status, lymph node status, distant metastasis, tumour grade, portal vein resection, microscopic
direct vascular invasion, T-stage and blood transfusion requirement significantly affected outcome on
univariate analysis. Distant metastasis (P = 0.040), percutaneous biliary drainage (P = 0.015) and blood
transfusion requirement (P = 0.026) were significant factors on multivariate analysis. Survival outcomes
improved and blood transfusion requirement was significantly reduced in the most recent time period.
Discussion: Blood transfusion requirement and preoperative percutaneous biliary drainage were iden-
tified as independent indicators of a poor prognosis following resection of PHCCA. Longterm survival can
be achieved following the aggressive surgical resection of this tumour, but the emergence of a clear
learning curve in our analyses indicates that these patients should be managed in high-volume centres in
order to achieve improved outcomes.
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Introduction
Cholangiocarcinoma, a primary tumour of the biliary epithelium,
accounts for 3% of all gastrointestinal malignancies, but has a
dismal prognosis.1 Cholangiocarcinoma can occur at any location
in the biliary tree, but is most commonly (60–70%) evident at the
confluence of the hepatic ducts; this manifestation is termed ‘hilar
cholangiocarcinoma’.2 Hilar cholangiocarcinoma was first
described in detail in 1965 by Gerald Klatskin and hence these
tumours are often termed ‘Klatskin tumours’.3 More recently, the
term ‘perihilar cholangiocarcinoma’ has been used to include both
intra- and extrahepatic cholangiocarcinomas affecting the hepatic
hilum as they are managed similarly.4 This paper considers both
This paper was presented at the American Hepato-Pancreato-Biliary Asso-
ciation 11th Annual Meeting, Miami, FL, USA.
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intra- and extrahepatic examples of this cholangiocarcin-
oma under the umbrella term ‘perihilar cholangiocarcinoma’
(PHCCA).
Perihilar cholangiocarcinoma tends to present late for several
reasons. The unobstructive lateral extension of the tumour com-
bined with the detergent properties of bile result in the late occur-
rence of the complete obstruction of the bile duct, which causes
jaundice, the most common form of presentation.5 This late pre-
sentation combined with the intimate relations of this tumour
with the portal vein, hepatic arteries and liver make PHCCA a
surgical challenge. Surgery remains the only curative therapy for
patients with PHCCA, although chemotherapy, radiotherapy and
photodynamic therapy are sometimes useful as adjuncts to surgi-
cal resection or as palliative therapy.6–8
The aim of this study was to assess the results of surgical resec-
tion for PHCCA over the last 15 years in a large Western hepato-
biliary tertiary referral centre and to establish which factors
significantly affect survival. Furthermore, by dividing the data into
three datasets for three consecutive time periods, we investigated
how practice has evolved and what impact this has had on patient
outcomes.
Materials and methods
Patient selection
Patients who underwent a first liver resection for PHCCA between
January 1994 and December 2008 were identified from a prospec-
tively maintained database containing all liver and biliary resec-
tions carried out at St James’s University Hospital, Leeds, UK.
Demographic data assessed included information on patient age,
gender, mode of presentation, pre-resection interventions and
investigations. Other data included operative findings, surgical
techniques, blood transfusion requirements, histopathology, and
morbidity and mortality. Perioperative mortality was defined as
death as an inpatient or within 30 days of surgery. Patients’ notes
were checked for database accuracy and follow-up visits were
arranged for follow-up completion. In addition to an analysis of the
entire group, datasets for three 5-year time periods were assessed
(Period 1: 1994–1998; Period 2: 1999–2003; Period 3: 2004–2008)
to investigate how practice and outcomes have evolved.
Preoperative workup
Contrast-enhanced magnetic resonance imaging (MRI) with mag-
netic resonance cholangiopancreatography (MRCP) and magnetic
resonance angiography (MRA) were used to assess the extent of the
tumour and its relationship to biliary and vascular structures. If
jaundice was present, a biliary drainage procedure was performed.
Endoscopic biliary drainage (EBD) was the preferred mode of
drainage, but percutaneous transhepatic biliary drainage (PTBD)
was often carried out prior to referral and was employed when EBD
was not possible. Early in the experience, preoperative biliary
drainage was used only in patients with a serum bilirubin level
>300 mmol/l (17.54 mg/dl), but jaundice was quickly recognized as
an adverse risk factor and thus for the last 10 years all patients with
a serum bilirubin level>50 mmol/l (2.92 mg/dl) have been drained.
Current practice is to drain only the planned liver remnant except
in cases of bilateral biliary sepsis, when both lobes require to be
drained. Computed tomography (CT) of the chest, abdomen and
pelvis was used to assess potential sites of metastatic disease. Diag-
nostic staging laparoscopy was employed routinely to assess for
peritoneal metastases. Since 2006, positron emission tomography
(PET) has also been used to assess for extrahepatic disease. Unre-
sectable disease was defined by the presence of definite peritoneal
disease or extrahepatic metastases other than regional lymph node
involvement, extensive bilobar liver metastases or macroscopic
para-aortic nodal disease. In the most recent time period (Period
3), patients with liver metastases have not been operated. Vascular
invasion was not considered a contraindication to surgical explo-
ration, except in patients aged >60 years with bilateral hepatic
artery encasement. Elevated neutrophil : lymphocyte ratios, indi-
cating a potential preoperative host inflammatory response to
tumour, were defined as a ratio > 5 and assessed retrospectively
using the hospital’s haematology records.
Surgical technique
Bile duct excision
All patients underwent a resection of the extrahepatic biliary tree
from the level of the upper border of the pancreas to the conflu-
ence of the left and right hepatic ducts. If the tumour extended
lower than the intrapancreatic portion of the common bile duct,
this was also removed and pancreaticoduodenectomy was consid-
ered. At the upper end of the biliary tree, the extent of biliary
resection has depended on the extent of hepatic resection required
and in recent years the technique of ‘anatomical’ right hepatic
trisectionectomy has been adopted when necessary.9 Recently,
routine frozen-section histopathology has also been used to guide
the extent of biliary resection. Biliary reconstruction in all patients
was performed by antecolic Roux-en-Y hepaticojejunostomy
without biliary stents.
Hepatic resection
Hepatic resection was carried out to include all segments of liver
involved by tumour or affected by planned loss of vascular supply
during surgery. Caudate lobectomy was planned and carried out
routinely, except in patients in whom operative difficulties
(mainly haemorrhage in the early period) indicated that this
would pose an extraordinary risk. In recent years, caudate lobec-
tomy has been performed in all patients. The techniques of right
and left hepatic trisectionectomy have been described in detail
previously.10,11
Vascular resection
Rather than routinely employing the ‘no-touch’ technique,5 con-
comitant portal vein resection and reconstruction have been
applied aggressively when macroscopic invasion was suspected at
surgery.12,13 Although some controversial problems remain,14–16
concomitant hepatic artery resection and reconstruction have
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been applied similarly except in patients aged > 60 years. In addi-
tion, portal vein arterialization has been considered as an alterna-
tive to hepatic artery reconstruction only when the latter was
impossible after hepatic artery resection.17,18 Reconstructions
avoided the use of grafts, although a saphenous vein graft was
needed to reconstruct a hepatic artery in one case.
Lymphadenectomy
Lymphadenectomy has included lymph nodes, lymphatic chan-
nels and nerves surrounding the portal vein and hepatic artery in
all patients. In Period 1, lymphadenectomy was regional. In Period
2, it was extended to include para-aortic nodes from the level of
the diaphragm to the aortic bifurcation, but this was found to be
associated with increased morbidity (mainly ascites requiring
diuretics or drainage for several weeks). In Period 3, lym-
phadenectomy was reduced to include the para-aortic nodes from
the level of the coeliac axis to the inferior mesenteric artery in
most patients. In elderly patients (aged > 70 years) or patients
with significant cardiopulmonary comorbidity, lymphadenec-
tomy has been limited to the regional nodes in an attempt to
reduce the risk for perioperative mortality.
Blood transfusion policy
Blood was transfused routinely if the haemoglobin level fell to
<8 g/dl. Fresh frozen plasma was transfused if the prothrombin
time rose to >30 s. Preoperative blood donation was not used in
any of these patients and although a cell saver system is used in our
transplant patients, it was not used in this series.
Histopathology
All procedures were performed at the same institution and all
specimens were reviewed by the same pathologist. Frozen-section
assessment of surgical margins was carried out if there was clinical
suspicion of margin involvement at the time of resection in
Periods 1 and 2 and routinely in Period 3. Tumours were staged
according to the tumour–node–metastasis (TNM) Classification
of Malignant Tumours by the International Union Against Cancer
(6th edition, 2002) for ‘extrahepatic bile duct cancer’.19 Therefore,
intrahepatic metastasis in patients was classified as distant
metastasis (including intrahepatic metastasis, peritoneal deposits
and positive para-aortic nodes) (M1). R0 resection was defined as
negative resection margins and negative radial margins on histol-
ogy; R1 resection was defined as the histological presence of
tumour at any margin, and R2 resection was defined as the
macroscopic presence of tumour or M1 disease.
Adjuvant treatment
Only in Period 3 was chemotherapy in the form of capecitabine
offered to patients following resection as part of the BILCAP trial.
Follow-up
Patients were followed up in outpatient clinics at 3 and 6 months
post-resection and then every 6 months until year 2. Following
this, patients attended clinic annually. Patients underwent a CT of
the chest, abdomen and pelvis in addition to assessments of
tumour markers (CEA [carcinoembryonic antigen] and CA19-9
[carbohydrate antigen 19-9]) and liver function tests at each clinic
visit until year 5. Subsequently, clinical examination, tumour
markers and liver function tests were carried out annually and CT
scans were performed at years 7 and 10. Since 2006, MRI and
PET-CT have been used if recurrent disease was suspected on
routine follow-up.
Statistical analysis
Continuous variables are presented as the median (range); cat-
egorical data are presented as the frequency and proportion (%).
Kaplan–Meier survival curves were drawn and log-rank statistics
calculated to assess which variables affected survival time. The Cox
proportional hazard model was used for multivariate analysis and
all variables that were significant or approaching significance (P <
0.1) were brought forward for analysis. The Kruskal–Wallis test was
used to analyse data for the three time periods. All statistical tests
were carried out using spss for Windows™Version 14.0 (SPSS, Inc.,
Chicago, IL, USA). Statistical significance was set at 5%.
Results
Patient characteristics
Between January 1994 and December 2008, 90 patients underwent
surgery for PHCCA at St James’s University Hospital, Leeds. The
surgical resection rate was 92% (83 patients). The 83 resected
patients included 48 men and 35 women, with a median age of 57
years (range: 25–81 years). The most common presentation was
jaundice; patients without jaundice presented with abdominal
pain.
Preoperative patient optimization
In total, 63 (76%) of the 83 resected patients required preoperative
biliary drainage. Endoscopic biliary drainage, PTBD, and both
EBD and PTBD were carried out in 40 (64%), 14 (22%) and nine
(14%) patients, respectively. Of the patients who underwent
drainage procedures, 47 (75%) were transferred from district hos-
pitals or other hepatobiliary centres following EBD or PTBD, and
two (4%) of these had received metallic stents. Of these 47
patients, 10 required further biliary interventions in Leeds prior to
surgery for inadequate relief of jaundice or drainage of planned
liver resection segments. Portal vein embolization was used in one
patient.
Surgical procedures
Liver resection with caudate lobectomy was carried out in 77
(93%) patients with Bismuth type III or IV lesions. In 55 patients
(71% of those undergoing liver resection), a right (n = 31) or left
(n = 24) hepatic trisectionectomy was required (Table 1). Only six
patients underwent a bile duct excision for reasons of patient
fitness when disease was limited to a Bismuth type I or type II
lesion. Portal vein resection and hepatic artery resection were
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required in 32 (39%) and eight (10%) patients, respectively. Of
these, seven (8%) patients underwent concomitant portal vein
and hepatic artery resection. In two cases, portal vein arterializa-
tion was carried out; these patients have been described in detail
elsewhere.18 The median length of the procedure was 390 min
(range: 120–630 min).
Tumour characteristics
The median macroscopic tumour size was 25 mm (range:
8–75 mm). R0 resection was achieved in 35 (42%) patients, R1
resection in 39 (47%) patients and R2 resection in nine (11%)
patients (liver metastasis, n = 4; peritoneal deposits, n = 2; para-
aortic nodes, n = 3). In terms of the histological differentiation of
the tumour, well differentiated adenocarcinoma was seen in 37
(45%) cases, moderate differentiation in 21 (25%) and poor dif-
ferentiation in 25 (30%). Perineural invasion was seen in 72 (89%)
patients. Two (2%) patients had stage T1 disease, 35 (43%) had
T2, 31 (38%) had T3 and 13 (16%) had T4 disease. Lymph node
infiltration was noted in 47 (57%) patients.
Morbidity and mortality
A total of 70 complications occurred in 52 (64%) patients
(Table 2). The rate of mortality was 7% (six patients): five deaths
followed episodes of sepsis related to liver insufficiency which
progressed to multi-organ failure, and the sixth patient died fol-
lowing a massive abdominal haemorrhage related to MRSA
(methicillin-resistant Staphylococcus aureus) sepsis with the devel-
opment of a hepatic artery aneurysm. The median length of stay
was 18 days (range: 5–137 days).
Survival
Figure 1 and Table 3 show overall survival and numbers at risk in
this series of patients compared with that in those patients
Table 1 Extent of resection in 83 patients undergoing surgery for
perihilar cholangiocarcinoma
Extent of resection Patients, n (%)
Right hepatic
trisectionectomy
(resection of hepatic
segments IV, V, VI, VII, VIII
 I) + bile duct excision
31 (37%)
(+pancreaticoduodenectomy
in two patients)
Left hepatic
trisectionectomy
(resection of hepatic
segments II, III, IV, V, VIII
 I) + bile duct excision
24 (29%)
Right hemihepatectomy
(resection of hepatic
segments V, VI, VII, VIII 
I) + bile duct excision
10 (12%) (+segment IVa
resection in two patients)
Left hemihepatectomy
(resection of hepatic
segments II, III, IV  I) +
bile duct excision
11 (13%)
Caudate (segment I)
resection alone + bile
duct excision
1 (1%)
Bile duct excision alone 6 (7%)
With portal vein resection 32 (39%)
With hepatic artery
resection
8 (10%)
With
pancreaticoduodenectomy
2 (2%)
Table 2 Morbidity in 83 patients undergoing surgery for perihilar
cholangiocarcinoma
Complication n (%)
Transient hepatic insufficiency 13 (16%)
Sepsis 12 (14%)
Wound infection 10 (12%)
Haemorrhage 9 (11%)
Bile leak 8 (10%)
Transient renal failure 5 (6%)
Gastrointestinal haemorrhage 3 (4%)
Chest infection 2 (2%)
Portal vein thrombosis 1 (1%)
Others 7 (8%)
O
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Resected 
Unresectable 
P = 0.005 
Figure 1 Kaplan–Meier curves for overall survival in resected and
unresected patients
Table 3 Overall survival in 90 patients with perihilar cholangiocarci-
noma: numbers at risk
Years
0 1 2 3 4 5
Resected 83 57 36 21 11 9
Unresectable 7 3 1 – – –
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deemed inoperable. The median length of follow-up was 20
months (range: 0–168 months). Overall survival was 70% at 1
year, 36% at 3 years, 20% at 5 years and 11% at 10 years following
surgical resection. The clinicopathological factors influencing
overall survival are shown in Table 4. Significant predictors of
decreased overall survival on univariate analysis were tumour size
>25 mm (P < 0.001), lack of R0 resection (P = 0.042), presence of
distant metastasis (P = 0.001), moderate or poor tumour differ-
entiation (P = 0.038), requirement for portal vein resection (P =
0.013), microscopic direct vascular invasion (P = 0.009), positive
lymph nodes (P < 0.001) and requirement for blood transfusion
(P = 0.009). The use of PTBD only approached significance on
univariate analysis (P = 0.095).
Significant predictors of decreased overall survival on multi-
variate regression were presence of distant metastasis (relative risk
[RR] 1.04–7.35; P = 0.040), use of PTBD (RR 1.18–4.38; P = 0.015)
and requirement for blood transfusion (RR 1.18–4.38; P = 0.015)
(Fig. 2, Table 5).
Table 4 Clinicopathological features predicting overall survival
Variable Patients,
n
5-year
survival, %
Median
survival,
months
Univariate
analysis,
P-value
Multivariate
analysis,
RR (95% CI)
Multivariate
analysis,
(P-value)
Male 48 17 22 0.494
Female 35 25 24
Age < 60 years 48 19 23 0.906
Age > 60 years 35 20 22
PTBD 23 6 20 0.095 2.27 (1.18–4.38) 0.015
No PTBD 56 29 26 1.00
ERCP 49 15 18 0.676
No ERCP 30 25 26
Trisectionectomy 55 21 20 0.397
No trisectionectomy 28 15 31
Size > 25 mm 36 8 13 <0.001 1.00 0.133
Size < 25 mm 39 31 38 1.90 (0.82–4.41)
R0 resection 38 33 31 0.042 0.59 (0.32–1.07) 0.083
R1/R2 resection 45 8 18 1.00
Distant metastasis 9 0 7 0.001 2.77 (1.04–7.35) 0.040
No distant metastasis 74 23 25 1.00
Well differentiated 37 27 31 0.038 0.56 (0.27–1.16) 0.121
Moderately/poorly differentiated 46 14 13 1.00
Portal vein resection 32 9 12 0.013 1.21 (0.63–2.32) 0.572
No portal vein resection 51 28 31 1.00
Hepatic artery resection 8 12 11 0.387
No hepatic artery resection 75 20 25
Microscopic direct vascular invasion 42 12 17 0.009 1.34 (0.67–2.66) 0.409
No microscopic direct vascular invasion 40 30 35 1.00
Perineural invasion 72 18 22 0.186
No perineural invasion 9 44 38
Positive lymph node invasion 47 13 15 0.015 1.85 (0.99–3.46) 0.053
Negative lymph node invasion 35 32 36 1.00
Complications 52 20 18 0.350
No complications 29 22 29
T-stage ½ 37 36 38 <0.001 0.72 (0.30–1.74) 0.459
T-stage ¾ 44 9 13 1.00
Blood transfusion 48 14 15 0.009 2.00 (1.09–3.69) 0.026
No transfusion 35 27 35 1.00
Neutrophil : lymphocyte ratio < 5 39 24 20 0.427
Neutrophil : lymphocyte ratio > 5 27 18 16
Data in bold are significant at P < 0.05.
RR, relative risk; 95% CI, 95% confidence interval; PTBD, percutaneous transhepatic biliary drainage; ERCP, endoscopic retrograde cholangiopancreatography.
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Subsequently, presence of distant metastasis, lymph node status
and margin status were used to stratify the patient group into four
groups, survival curves for which are shown in Fig. 3, Table 6.
Patients with R0-M0 with negative lymph nodes (R0-M0-N0)
achieved a 5-year survival rate of 49% (Fig. 3).
Comparison of outcomes in the three time periods
The clinicopathological differences observed among the three dif-
ferent time periods (Period 1, 1994–1998; Period 2, 1999–2003;
Period 3, 2004–2008) are shown in Table 7. Although we insti-
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Figure 2 Survival curves according to (A) distant metastasis (multi-
variate analysis, P = 0.040; hazard ratio [HR] 2.27, 95% confidence
interval [CI] 1.04–7.35), (B) percutaneous transhepatic biliary drain-
age (PTBD) (multivariate analysis, P = 0.015; HR 2.27, 95% CI
1.18–4.38) and (C) blood transfusion requirement (multivariate analy-
sis, P = 0.026; HR 2.00, 95% CI 1.09–3.69)
Table 5 Survival analyses in 83 patients undergoing resection for
perihilar cholangiocarcinoma according to distant metastasis, per-
cutaneous transhepatic biliary drainage (PTBD) and blood transfu-
sion requirement: numbers at risk
Years
0 1 2 3 4 5
(A)
No distant metastases 74 55 34 21 11 9
Distant metastases 9 2 2 1 – –
(B)
PTBD 23 15 8 6 1 –
No PTBD 56 39 25 16 10 9
(C)
No blood transfusion 26 21 15 12 6 4
Blood transfusion 41 24 13 8 4 4
R1-N1-M0 
R1-N0-M0 
R0-N1-M0 
R0-N0-M0 
Years post-resection
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Figure 3 Subgroup analysis by resection status, lymph node status
and presence of distant metastasis. R0, microscopic curative resec-
tion; R1, macroscopic curative resection; R2, macroscopic non-
curative resection; M0, absence of distant metastasis; M1, presence
of distant metastasis; N0, absence of lymph node metastasis; N1,
presence of lymph node metastasis
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gated no major differences in operative procedures across the
three periods, we succeeded in reducing the rate of perioperative
blood transfusion requirement from 89% in Period 1 to 33% in
Period 3 (P < 0.001). The postoperative mortality rate in Period 3
(6%) was lowest. In terms of tumour characteristics, only the
frequency of patients with distant metastasis decreased signifi-
cantly period by period (P = 0.022). The rates of R0 resection in
Periods 1, 2 and 3 were 39%, 52% and 44%, respectively.
Survival curves for the three periods are shown in Fig. 4
(Table 8). The number of resected patients doubled between
Periods 1 and 3, from 18 to 36. Five-year survival rates for Periods
1, 2 and 3 were 22%, 14% and 25%, respectively. Period 3 showed
the best survival, although the degree of improvement did not
reach statistical significance (Periods 1 vs. 3, P = 0.225; Periods 2
vs. 3, P = 0.108; Periods 1 vs. 2, P = 0.579). However, it should be
noted that 1-year survival post-surgery significantly improved
from 50% in Period 1 to 62% in Period 2 and 86% in Period 3
(Kruskal–Wallis test, P = 0.030).
Discussion
Surgical resection of PHCCA remains a formidable surgical chal-
lenge and our overall results are comparative with those of other
large Western series.20–25 An aggressive surgical approach was
employed, similar to that seen at Nagoya University Graduate
School of Medicine, which has the greatest degree of experience
in the management of PHCCA of anywhere in the world.26 In
terms of prognostic factors, the results reported here are similar
to those of the Nagoya experience in that on univariate analysis
they show that R0 status, lymph node invasion, presence of
distant metastasis, portal vein invasion, histological grade and
microscopic direct vascular invasion are important in determin-
ing outcome.27 The rate of resectability in the current series
(92%) is relatively high compared with those reported in other
series.28 However, this comparison is not always useful because
preoperative workup protocols and staging investigations differ
among units.
There is some concern that the rate of R0 resection has not
significantly increased over time, but this may reflect the fact
that resection is more often attempted in patients with more
locally advanced disease as experience increases. The pursuit of
R0 resections must be balanced against the need to offer surgery
to all patients for whom it might have potential benefit and to
carry out extensive resections safely. The increased use of intra-
operative frozen-section histopathology may allow us to improve
the R0 resection rate. However, there have been reports that
frozen sections can be misleading29 and extending resections in
accordance with the indications of frozen sections may not
improve outcomes.27 Many Eastern centres, including that in
Nagoya, advocate portal vein embolization as a useful adjunct to
surgery to improve postoperative outcomes following extended
resection for PHCCA, perhaps allowing more extensive resection
to ensure negative resection margins.30 As yet, no data from ran-
domized trials are available, but the majority of patients in this
series presented with lobar atrophy caused by vascular invasion
and thus portal vein embolization was not thought to be ben-
eficial. The histological grade of resected tumours appears to
represent another area of difference between the series reported
from, respectively, our unit and that at Nagoya. Poor tumour
differentiation was observed in 30% of resected patients in the
present series, but in only 7% of patients reported in a
recent series from Nagoya.4 More detailed analysis is required to
assess whether there is a significant difference in tumour
grade in patients presenting to Eastern and Western centres as
tumour grade has been shown to significantly affect longterm
outcomes.4,23,31
The finding that PTBD significantly impaired overall survival
on multivariate analysis has not emerged before in a Western
series, although it was recently described in two Eastern series.32,33
Preoperative biliary drainage is advocated prior to resection for
PHCCA as it reduces complications that arise from major resec-
tions in cholestatic livers.34 However, PTBD carries a significant
risk for direct tumour seeding to intrahepatic, peritoneal and even
pleural sites, all of which we have seen.35–38 Percutaneous transhe-
patic biliary drainage can also directly result in portal vein throm-
bosis, although this seems comparatively rare and was not seen in
this series.39 The data demonstrate that PTBD is an independent
predictor of a poor outcome; it is unclear whether this is simply
the result of tumour seeding or whether other factors may be
implicated. More recently, evidence from a retrospective series
published by the Hokkaido University Graduate School of Medi-
cine, Sapporo, Japan suggested that, not only is PTBD harmful,
but nasobiliary endoscopic drainage has advantages over EBD.33
These include decreased stent occlusions, decreased episodes of
cholangitis and increased diagnostic accuracy if complications
arise.33 Endoscopic biliary drainage may increase the risk for
Table 6 Subgroup analysis by resection status, lymph node
status and presence of distant metastasis: numbers at risk and
overall survival
Numbers at risk at years:
0 1 2 3 4 5
R0-N0-M0 16 13 11 8 6 6
R0-N1-M0 19 14 8 6 2 1
R1-N0-M0 17 13 10 4 2 1
R1-N1-M0 21 15 6 3 1 1
Overall survival at:
P = 0.195
P = 0.144
P = 0.089
1 year 3 years 5 years
R0-N0-M0 81 66 49
R0-N1-M0 68 41 25
R1-N0-M0 82 38 14
R1-N1-M0 71 20 7
P = 0.264
R0, microscopic curative resection; R1, macroscopic curative resection;
R2, macroscopic non-curative resection; M0, absence of distant
metastasis; M1, presence of distant metastasis; N0, absence of lymph
node metastasis; N1, presence of lymph node metastasis.
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cholangitis, which impairs hepatic regeneration post-resection,33
but this was not seen in our series, in which the main issues
referred to difficulty in duct cannulation and potential risk for
pancreatitis. These issues can only be addressed by a randomized
controlled trial, but this would be difficult to carry out. Thus, until
further data are available, we will continue to use EBD as a first-
line biliary drainage procedure as part of our protocol. As the
majority of our patients undergo EBD and/or PTBD prior
to referral, this factor is currently outwith our control. This
suggests that national guidelines should be updated to improve
overall patient management because there are currently no clear
recommendations.40
Our investigation indicated that blood transfusion requirement
is an independent indicator of a poor prognosis following surgical
Table 7 Clinicopathological differences in patient data among three time periods
Variable Period 1
1994–1998, %
(n = 18)
Period 2
1999–2003, %
(n = 29)
Period 3
2004–2008, %
(n = 36)
Kruskal–Wallis,
P-value
Male 56 52 64 0.603
Age < 60 years 44 31 50 0.303
Percutaneous transhepatic biliary drainage 12 48 21 0.076
Endoscopic retrograde cholangiopancreatography 88 52 60 0.058
Trisectionectomy 61 72 64 0.786
Portal vein resection 33 41 39 0.859
Hepatic artery resection 6 10 8 0.407
Operation time, mins, median (range) 330 (240–480) 395 (165–540) 390 (120–630) 0.835
Blood transfusion 89 69 33 <0.001
Complications 56 61 71 0.470
Elevated neutrophil : lymphocyte ratio 33 57 33 0.191
Postoperative mortality 11 7 6 0.727
Postoperative stay, days, median (range) 17 (8–24) 17 (10–59) 23 (5–137) 0.171
Size > 25 mm 50 56 43 0.657
Well differentiated 50 52 36 0.399
Microscopic direct vascular invasion 56 36 61 0.123
Perineural invasion 88 93 86 0.696
T-stage ½ 56 68 43 0.143
Positive lymph nodes (N1) 50 57 61 0.741
Distant metastasis (M1) 28 10 3 0.022
R0 resection 39 52 44 0.679
Median survival, months 11 17 31 0.716
Data in bold are significant at P < 0.05.
Years post-resection 
O
ve
ra
ll 
su
rv
iv
al
, % 2004–2008
1999–2003
1994–1998
Figure 4 Kaplan–Meier survival curves for the three time periods
analysed. Period 1: 1994–1998; Period 2: 1999–2003; Period 3:
2004–2008. Periods 1 vs. 2: P = 0.579; Periods 1 vs. 3: P = 0.225;
Periods 2 vs. 3: P = 0.108
Table 8 Survival data for Periods 1, 2 and 3: numbers at risk
Years
0 1 2 3
1994–1998 18 9 7 6
1999–2003 29 18 12 9
2004–2008 36 30 17 7
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resection for PHCCA. However, this has been reported previously
in a smaller series in which it was found to be significant only on
univariate analysis.41 In other malignancies, transfusion require-
ment is thought to worsen oncological outcomes, probably as a
result of the immunosuppressive effect of transfused blood prod-
ucts.41 Hence, the significant reduction in the level of requirement
for blood transfusion in the most recent time period, which is
probably attributable to our increase in experience, can only
benefit patient outcomes.
Survival analyses revealed that, in the M1 group, surgery
achieved very poor survival at a rate similar to that in unresec-
table patients. In addition, survival analyses according to lymph
node metastasis in patients with M0 disease who underwent R0
or R1 resection demonstrated that the R0-N0-M0 group
achieved excellent survival (5-year survival rate: 49%) and the
R1-N0-M0 group did less well. Survival rates in the R0-N1-M0
and R1-N1-M0 groups were only 25% and 7%, respectively
(Fig. 3). These results show that surgery alone may be insuffi-
cient to conquer PHCCA with lymph node metastasis, even if R0
resection can be achieved.
Previous reports have identified both an elevated neutro-
phil : lymphocyte ratio and the presence of postoperative com-
plications as important factors affecting survival in colorectal
liver metastasis (CLM).42,43 However, in the analysis shown here,
elevation of the neutrophil : lymphocyte ratio, indicating a
potential preoperative inflammatory response to tumour, did
not affect survival in PHCCA. This may be because the neutro-
phil : lymphocyte ratio in PHCCA can also be increased by
cholestasis and/or cholangitis. In addition, analyses of postop-
erative morbidity demonstrated that postoperative complica-
tions had no influence on survival in PHCCA. This may reflect
the fact that postoperative complications occur more frequently
in PHCCA patients than in patients undergoing hepatic resec-
tion for CLM.
One-year survival rates significantly increased over the three
time periods (from 50% to 86%), as did median survival times
(from 11 to 37 months) in response to an evolution in practice. In
Period 1, patients often presented at a late stage, which, combined
with our relatively low experience, contributed to poorer results.
By the intermediate period (Period 2), it was clear that aggressive
resection would lead to improved outcomes. Most recently
(Period 3), as our approach has matured and patient selection has
improved, the best results have become apparent. This can be
measured by the lower postoperative mortality and higher 1- and
5-year survival rates. It is also of note that our unit has seen no
postoperative mortality since 2004. In addition, although we con-
tinue to carry out predominantly hepatic trisectionectomy with
extensive lymph node dissection and increasingly complex vascu-
lar reconstructions, requirements for blood transfusion are sig-
nificantly reducing with experience, in line with decreases
observed in major Eastern centres.26,43,44
Although the body of literature describing results following
surgical resection for PHCCA is increasing, even the largest hepa-
tobiliary centres have considerably less experience in this area than
they do in other diseases, such as CLM or hepatocellular carci-
noma (HCC). During the 15-year period reported here, 1300
patients with CLM and 140 patients with HCC underwent surgi-
cal resection at St James’s Hospital, compared with only 83 with
PHCCA. This fact and the clear surgical learning curve that is
apparent in the results presented here support the centralizing of
resources for PHCCA surgery.45 In addition, access to newly avail-
able knowledge is important in the management of PHCCA.
Therefore, four senior surgeons from Nagoya University Graduate
School of Medicine, including two of the present authors (TI and
YS), have been appointed as clinical researchers at Leeds since
2003, and the management of patients with PHCCA has been
subject to much discussion. The present data suggest that further
reductions in blood transfusion requirements and the avoidance
of PTBD will continue to improve results. The next main chal-
lenge in maximizing outcomes of PHCCA patients will refer to
increasing the rate of R0 resection. This can probably only be
achieved by earlier diagnosis and referral, although the introduc-
tion of an effective neoadjuvant therapy may help. In addition,
improved preoperative staging, which may be supported by the
advent of PET-CT,46 should ensure that only patients in whom
benefit can be achieved undergo this major surgical intervention.
In summary, we have identified that blood transfusion require-
ment and preoperative percutaneous biliary drainage represent
independent indicators for a poor prognosis following resection
of PHCC and thus are areas for potential improvement. Longterm
survival can be achieved following aggressive surgical resection
of this tumour, but it is apparent that these patients should be
managed in high-volume centres in order to improve their
outcomes.
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